We showed that TFAP2C knockdown enhanced the anti-tumor effects of cisplatin in vivo and in vitro by reducing the levels of EGFR and NF-κB activation, thereby providing a new idea for improving the efficacy of cisplatin. This evidence concerns the gene NFKB1 and neoplasm.